ANDAORALSYRUP
Approved
Jul 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
POLMON (dexchlorpheniramine maleate) by R-Pharm US is clinical pharmacology dexchlorpheniramine maleate is an antihistamine with anticholinergic (drying) and sedative side effects. First approved in 2018.
Drug data last refreshed 18h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Dexchlorpheniramine maleate is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
Started Sep 2012
310 enrolled
Eczema
Company
Worked on POLMON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.